Akebia Therapeutics, Inc.
NASDAQ:AKBA
2.06 (USD) • At close April 17, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 160.18 | 194.623 | 292.602 | 213.578 | 295.307 | 335.001 | 207.742 | 177.984 | 1.535 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 63.177 | 74.149 | 84.796 | 153.394 | 295.908 | 145.336 | 7.685 | 0.617 | 115.785 | 0.096 | 23.263 | 0 | 0 |
| Brutowinst
| 97.003 | 120.474 | 207.806 | 60.184 | -0.601 | 189.665 | 200.057 | 177.367 | -114.25 | -0.096 | -23.263 | 0 | 0 |
| Brutowinstmarge
| 0.606 | 0.619 | 0.71 | 0.282 | -0.002 | 0.566 | 0.963 | 0.997 | -74.43 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 37.652 | 63.079 | 129.114 | 147.852 | 218.485 | 322.969 | 291.068 | 230.893 | 115.785 | 43.016 | 25.398 | 10.782 | 5.632 |
| Algemene en administratieve kosten
| 0 | 0 | 141.874 | 177.65 | 157.356 | 152.984 | 87.128 | 27.008 | 22.21 | 18.497 | 12.542 | 5.152 | 2.891 |
| Verkoop- en marketingkosten
| 0 | 100.233 | -3.175 | 174.161 | 153.947 | 149.455 | 87.061 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 106.545 | 100.233 | 141.874 | 174.161 | 153.947 | 149.455 | 87.061 | 27.008 | 22.21 | 18.497 | 12.542 | 5.152 | 2.891 |
| Overige kosten
| 3.278 | 3.418 | -12.541 | 3.489 | 3.409 | 3.529 | 6.235 | 0.204 | -0.188 | 0.287 | 0.7 | 1.05 | 1.971 |
| Bedrijfskosten
| 147.475 | 166.73 | 270.988 | 325.502 | 375.841 | 475.953 | 378.196 | 257.901 | 137.995 | 61.513 | 37.94 | 15.933 | 8.523 |
| Bedrijfsresultaat
| -50.472 | -46.256 | -63.182 | -265.318 | -376.442 | -286.288 | -178.139 | -79.917 | -136.46 | -61.513 | -37.94 | -15.933 | -8.523 |
| Bedrijfsresultaat ratio
| -0.315 | -0.238 | -0.216 | -1.242 | -1.275 | -0.855 | -0.858 | -0.449 | -88.899 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| -18.938 | -5.669 | -13.447 | -17.522 | -5.631 | -0.002 | 6.235 | 3.003 | 0.713 | 0.497 | 0.906 | 2.766 | 0.327 |
| Inkomen voor belasting
| -69.41 | -51.925 | -92.562 | -282.84 | -383.457 | -286.29 | -171.904 | -76.914 | -135.747 | -60.716 | -37.034 | -13.167 | -8.196 |
| Inkomen voor belasting ratio
| -0.433 | -0.267 | -0.316 | -1.324 | -1.299 | -0.855 | -0.827 | -0.432 | -88.435 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0 | 0 | 13.447 | -37.97 | -33.59 | -6.631 | -28.338 | -2.799 | -0.901 | -0.51 | -0.206 | 1.753 | 1.605 |
| Nettowinst
| -69.41 | -51.925 | -106.009 | -244.87 | -349.867 | -279.659 | -171.904 | -76.914 | -135.747 | -60.716 | -37.034 | -13.167 | -8.196 |
| Nettowinstmarge
| -0.433 | -0.267 | -0.362 | -1.147 | -1.185 | -0.835 | -0.827 | -0.432 | -88.435 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.33 | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 | -0.68 | -0.81 |
| Verwaterde WPA
| -0.33 | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 | -0.68 | -0.81 |
| EBITDA
| -13.721 | -6.868 | -43.259 | -225.96 | -340.996 | -247.642 | -178.094 | -76.057 | -136.164 | -61.417 | -37.891 | -12.462 | -6.551 |
| EBITDA ratio
| -0.086 | -0.035 | -0.148 | -1.058 | -1.155 | -0.739 | -0.857 | -0.427 | -88.706 | 0 | 0 | 0 | 0 |